Trial Profile
(Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) - A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary) ; Tranexamic acid
- Indications Surgical blood loss
- Focus Therapeutic Use
- Acronyms CONSERV - 2
- Sponsors Cubist Pharmaceuticals
- 05 Jun 2014 New trial record